Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu
Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat
Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
G directly administered antiretroviral therapy with self-administered therapy in opioid treatment programs, Baltimore, Maryland, 2006?010.Differencea (95 CI)SAT (N = 52) Virologic and immunologic outcomes Average proportion with HIV RNA ,50 copies/mL during interventionb Average proportion with HIV RNA ,400 copies/mL during intervention Average change from baseline in log10 HIV RNA during interve